Excellent outcomes reported for first targeted therapy for pediatric Hodgkin lymphoma
Results from a collaborative multi-site clinical trial show the success of adding brentuximab vedotin, reducing radiation
2021-04-08
(Press-News.org) Scientists are reporting results of the first frontline clinical trial to use targeted therapy to treat high-risk pediatric Hodgkin lymphoma. The study showed that the addition of brentuximab vedotin achieved excellent outcomes, reduced side effects, and allowed for reduced radiation exposures.
The study was the result of work by a multi-site consortium dedicated to pediatric Hodgkin-lymphoma. Collaborating institutions include St. Jude Children's Research Hospital, Stanford University School of Medicine, Dana-Farber Cancer Institute, Massachusetts General Hospital, Maine Children's Cancer Program and OSF Children's Hospital of Illinois.
A paper detailing the findings was published today in the Journal of Clinical Oncology.
A new kind of therapy
Brentuximab vedotin is an anti-CD30 antibody drug conjugate. The drug, which is already approved to treat adults with Hodgkin lymphoma, is targeted specifically to Hodgkin Reed Sternberg cells (cancer cells in Hodgkin lymphoma). Brentuximab vedotin delivers the medicine directly where it is needed.
"I think of brentuximab vedotin as a smart drug," said first and corresponding author Monika Metzger, M.D., St. Jude Departments of Oncology and Global Pediatric Medicine. "Unlike conventional chemotherapy, which can have wide-ranging effects on all cells of the body, this drug knows to go directly to the Hodgkin lymphoma cells - maximizing its effect while minimizing side effects."
This phase 2 clinical trial replaced the chemotherapy drug vincristine with brentuximab vedotin in the frontline (first therapy given) treatment regimen. The regimen included other chemotherapy agents and radiation when needed. Vincristine is associated with neuropathy. Removing it from the regimen resulted in patients reporting a reduction in this symptom.
Overall three-year survival for the trial was 99%. Of the 77 patients enrolled in the study, 35% were spared radiation. When radiation was needed, it was precisely tailored, and doses were reduced when possible.
"We have already reduced the use of radiation for low-risk Hodgkin lymphoma patients. In this study we've shown that it is also possible to either omit or reduce the extent of radiation for high-risk patients, using highly focal methods such as proton beam radiation or intensity modulated radiation," said co-senior author Matthew Krasin, M.D., St. Jude Department of Radiation Oncology.
The researchers concluded that brentuximab vedotin in the frontline treatment of pediatric high-risk Hodkgin lymphoma is tolerable, reduced radiation exposure and produced excellent outcomes. Brentuximab vedotin is currently being incorporated into other national trials for the care of pediatric patients with Hodgkin lymphoma.
"Being able to offer Hodgkin lymphoma patients a targeted therapy in the frontline setting is an exciting development," said co-senior author Melissa Hudson, M.D., St. Jude Cancer Survivorship Division director. "We are constantly learning from research and applying new findings to the next iteration of clinical trials."
INFORMATION:
The study's authors include Michael Link, Susan Hiniker and Sarah Donaldson, Stanford University School of Medicine; Amy Billett, Nemours/Alfred I. DuPont Hospital for Children (formerly Dana-Farber Cancer Institute); Torunn Yock and Alison Friedmann, Massachusetts General Hospital; Sandra Luna-Fineman, University of Colorado (formerly Stanford University); Eric Larson, Maine Children's Cancer Program; and Pedro de Alarcon, OSF Children's Hospital of Illinois. Other St. Jude authors are Jamie Flerlage, John Lucas Jr., Belinda Mandrell, Matthew Ehrhardt, Nickhill Bhakta, Sue Kaste, Barry Shulkin, Zhaohua Lu and Chen Li.
The study was a multi-center, investigator-initiated, single-arm trial sponsored by Seattle Genetics (IND (#118603). The research at St. Jude was funded in part by grants from the National Cancer Institute (P30CA021765), and ALSAC, the fundraising and awareness organization of St. Jude.
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
2021-04-08
The Mfd protein repairs bacterial DNA, but can also, to scientists' surprise, promote mutation.
Bacterial mutations can lead to antibiotic resistance.
Understanding this second "role" of the Mfd protein opens up opportunities for combating antibiotic resistance, and also the resistance of tumours to anti-cancer drugs and therapies.
Using a specialized protein, all bacteria are capable of rapidly and effectively repairing damage to their DNA from UV. However, this mutation frequency decline (Mfd) protein plays another role and causes mutations. A team involving ...
2021-04-08
In cancer, personalised medicine takes advantage of the unique genetic changes in an individual tumour to find its vulnerabilities and fight it. Many tumours have a higher number of mutations due to a antiviral defence mechanism, the APOBEC system, which can accidentally damage DNA and cause mutations.
Researchers at IRB Barcelona led by Dr. Travis Stracker and Dr. Fran Supek have found the HMCES enzyme to be the Achilles heel of some lung tumours, specifically those with a higher number of mutations caused by the APOBEC system.
"We have discovered that blocking HMCES is very damaging to cells with an activated ...
2021-04-08
Hispanic immigrants of working age -- 20 to 54 years old -- are over 11 times more likely to die of COVID-19 than U.S.-born men and women who are not Hispanic, according to a USC study of California death certificate data from 2020.
The study, published Monday in the END ...
2021-04-08
QUT researchers have used carbon dots, created from human hair waste sourced from a Brisbane barbershop, to create a kind of "armour" to improve the performance of cutting-edge solar technology.
In a study published in the Journal of Materials Chemistry A, the researchers led by Professor Hongxia Wang in collaboration with Associate Professor Prashant Sonar of QUT's Centre for Materials Science showed the carbon nanodots could be used to improve the performance of perovskites solar cells.
Perovskites solar cells, a relatively new photovoltaic technology, are seen as the best PV candidate to deliver low-cost, highly efficient solar electricity in coming years. ...
2021-04-08
EUGENE, Ore. -- April 8, 2021 -- Researchers exploring the developing central nervous system of fruit flies have identified nonelectrical cells that transition the brain from highly plastic into a less moldable, mature state.
The cells, known as astrocytes for their star-like shapes, and associated genes eventually could become therapeutic targets, said University of Oregon postdoctoral researcher Sarah Ackerman, who led the research.
"All of the cell types and signaling pathways I looked at are present in humans," Ackerman said. "Two of the genes that I ...
2021-04-08
More than a third of the Antarctic's ice shelf area could be at risk of collapsing into the sea if global temperatures reach 4°C above pre-industrial levels, new research has shown.
The University of Reading led the most detailed ever study forecasting how vulnerable the vast floating platforms of ice surrounding Antarctica will become to dramatic collapse events caused by melting and runoff, as climate change forces temperatures to rise.
It found that 34% of the area of all Antarctic ice shelves - around half a million square kilometres - including 67% of ice shelf area on the Antarctic Peninsula, would be at risk of destabilisation under 4°C of warming. Limiting temperature ...
2021-04-08
INDIANAPOLIS--Worldwide, 1 in 4 people will suffer from a depressive episode in their lifetime.
While current diagnosis and treatment approaches are largely trial and error, a breakthrough study by Indiana University School of Medicine researchers sheds new light on the biological basis of mood disorders, and offers a promising blood test aimed at a precision medicine approach to treatment.
Led by Alexander B. Niculescu, MD, PhD, Professor of Psychiatry at IU School of Medicine, the study was published today in the high impact journal Molecular Psychiatry . The work builds on previous research conducted by Niculescu and his colleagues into blood biomarkers that track suicidality as well as pain, post-traumatic stress ...
2021-04-08
The almost 15-million-year-old Nördlinger Ries is an asteroid impact crater filled with lake sediments. Its structure is comparable to the craters currently being explored on Mars. In addition to various other deposits on the rim of the basin, the crater fill is mainly formed by stratified clay deposits. Unexpectedly, a research team led by the University of Göttingen has now discovered a volcanic ash layer in the asteroid crater. In addition, the team was able to show that the ground under the crater is sinking in the long term, which provides important ...
2021-04-08
LOUISVILLE, Ky. - When a new drug is being developed, the first question is, "Does it work?" The second question is, "Does it do harm?" No matter how effective a therapy is, if it harms the patient in the process, it has little value.
Doctoral student Robert Skolik and Associate Professor Michael Menze, Ph.D., in the Department of Biology at the University of Louisville, have found a way to make cell cultures respond more closely to normal cells, allowing drugs to be screened for toxicity earlier in the research timeline.
The vast majority of cells used for biomedical research are derived from cancer tissues stored in biorepositories. They are cheap to maintain, easy to grow and multiply quickly. Specifically, ...
2021-04-08
PISCATAWAY, NJ - Adolescents who frequently see billboard or storefront advertisements for recreational cannabis are more likely to use the drug weekly and to have symptoms of a cannabis use disorder, according to a new study in the Journal of Studies on Alcohol and Drugs.
Despite use being illegal for those below age 21 even in states that have approved recreational marijuana, "legalization may alter the ways that youth use cannabis," write the study authors, led by Pamela J. Trangenstein, Ph.D., M.P.H., of the University of North Carolina at Chapel Hill.
An increasing number of states have legalized or are considering legalizing recreational marijuana, and public concern over the risks of cannabis use has declined in recent ...
LAST 30 PRESS RELEASES:
[Press-News.org] Excellent outcomes reported for first targeted therapy for pediatric Hodgkin lymphoma
Results from a collaborative multi-site clinical trial show the success of adding brentuximab vedotin, reducing radiation
